Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Point Therapeutics (MM) Charts. Click Here for more Point Therapeutics (MM) Charts.](/p.php?pid=staticchart&s=N%5EPOTP&p=8&t=15)
Point Therapeutics, Inc. (NASDAQ: POTP) presented a
preclinical poster on the Company's lead diabetes compound, PT-630, at
the Endocrine Society Annual Meeting on Monday, June 26, 2006. PT-630
is an inhibitor of DPP-4, which is a widely recognized target for the
treatment of diabetes.
During this poster presentation, the Company presented
side-by-side experiments in Zucker Diabetic Fatty (ZDF) rats comparing
PT-630 to both a cyanopyrrolidine (CP) DPP-4 inhibitor and to
metformin. These preclinical data lead the Company to conclude that:
-- With a single dose administration, PT-630 demonstrates longer
term benefits in both elevation of GLP-1 levels {24 and 48
hours post oral glucose tolerance test (OGTT)} and lowering of
plasma glucose (4 hours post OGTT) at later times than the
CP-inhibitor in animals.
-- With chronic administration, PT-630 is differentiated from
both the CP-inhibitor and metformin in animals. After 44 days
of daily dosing, PT-630 was more effective than the other two
study compounds in improving parameters associated with the
progression of type 2 diabetes. Specifically, there were
improvements in whole body sensitivity to insulin, a 50%
reduction in fasting plasma triglycerides and glucose levels
and a 1.7% reduction (a 26.4% reduction compared to the
controlled treated group) in HbA1c. There were no such
reductions in triglycerides and glucose levels with metformin
and the CP-inhibitor, and HbA1c was only reduced by 0.9% and
0.5%, respectively, with metformin and the CP-inhibitor.
A copy of the poster can be found on the Company's Web site
www.pther.com.
About PT-630:
PT-630, Point Therapeutics' lead diabetes compound, is an
inhibitor of DPP-4, which is a widely recognized target in the
treatment of diabetes. DPP-4 degrades the active form of GLP-1, an
intestinal peptide hormone responsible for regulating blood glucose
levels. When DPP-4 is inhibited, it leads to an elevation in the
circulating pool of active GLP-1, thereby greatly improving the
control of blood glucose levels in type 2 diabetes. Active GLP-1 is
also thought to have beneficial effects on pancreatic beta cell mass.
About Point Therapeutics, Inc.:
Point is a Boston-based biopharmaceutical company developing a
portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer,
type 2 diabetes and as vaccine adjuvants. Point is currently studying
its lead product candidate, talabostat, in two Phase 3 trials in
non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic leukemia,
and in combination with gemcitabine in metastatic pancreatic cancer.
In addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes and PT-510 as a
vaccine adjuvant.
Certain statements contained herein are not strictly historical
and are "forward looking" statements as defined in the Private
Securities Litigation Reform Act of 1995. This information includes
statements with respect to the company's clinical development programs
and the timing of initiation and completion of its clinical trials.
Forward-looking statements are statements that are not historical
facts, and can be identified by, among other things, the use of
forward-looking language, such as "believes," "feels," "expects,"
"may," "will," "should," "seeks," "plans," "schedules to," "projects,"
"anticipates" or "intends" or the negative of those terms, or other
variations of those terms of comparable language, or by discussions of
strategy or intentions. A number of important factors could cause
actual results to differ materially from those projected or suggested
in the forward looking statement, including the risk factors described
in Point's quarterly report on Form 10-Q for the quarter ended March
31, 2006 and from time to time in Point's periodic and other reports
filed with the Securities and Exchange Commission.